Search
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigationalcompare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Olive oil
go.drugbank.com/drugs/DB09567ApprovedInvestigationalUsed as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Pyridoxine
go.drugbank.com/drugs/DB00165ApprovedInvestigationalNutraceuticalVet approvedPyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. … It is also used in combination with [DB00366] (as the commercially available product Diclectin) for the treatment of nausea and vomiting in pregnancy.
Mixtures: COMPLEJO B EN KOLA GRANULADA, COMPLEJO B EN KOLA GRANULADACategories: Vitamin B ComplexSibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnSibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. … In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
PF-04937319
go.drugbank.com/drugs/DB15009InvestigationalPF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization. … [A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191]
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia.
Ondansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnand use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis. … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.
Products: ONDANSETRON EG, EURODANATP synthase F(1) complex subunit delta, mitochondrial
go.drugbank.com/bio_entities/BE0000484TargetEnzymeHumansATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit delta, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated
Polypeptides: ATP synthase F(1) complex subunit delta, mitochondrial